07.27.07
$2.4 Billion ($8.6B Total)
Key Executives:
Tsuyoshi Kikukawa, Representative Director and President
Masaaki Terada, Director, Sr. Exec. Managing Officer
Tsuyoshi Kikukawa, President, Olympus Corp.
Haruhito Morishima, President, Olympus Medical Systems Corp.
Rick Harbuck, Group VP, Olympus America, Medical Systems Group
Michael C. Woodford, Exec. Managing Director, Olympus Medical Systems Europa GmbH
No. of Employees: 33,022
World Headquarters: Tokyo, Japan
For the year ended March 31, 2006, overall net sales for Olympus Corp. exceeded $8.6 billion, up 20.2% from the prior year. FY 2007, which closed at the end of March, didn’t quite measure up to the gains seen in 2006 but did close with an 8.6% gain.
Solid financial growth and a wide array of new product offerings contributed to a steady year for Olympus Medical Systems, which continues to explore new methods on expanding its reach domestically and overseas.
Olympus Medical Systems obtained solid marks with 15.5% growth of $2.35 billion reported in net sales in FY 2006. The bulk of sales came from overseas, with $1.7 billion attributed to international sales and more than $600 million in sales reported domestically. The largest growth between FY 2005 and FY 2006 occurred in Asia (48.9%), with double-digit increases also seen in North America (16.9%), Japan (11.3%), Europe (10%) and other regions (27%).
The company closed its FY 2007, ended March 31, with sustained growth in net sales totaling $2.7 billion, a 17% increase from FY 2006. Once again, the company achieved a double-digit increase (22.2%) overseas, but sales were flat (2.5% growth) domestically.
The company’s stronghold in the endoscope product line reaped 18.5% growth in FY 2006, reaching $1.5 billion in sales. In FY 2007, sales grew another 22% over the prior year, reaching $1.8 billion. Sales of minimally invasive products, which include surgical endoscopes and endo-therapy devices, grew 10.1% to $806 million in FY 2006 and climbed another 7.2% in FY 2007 to $836 million.
New products continue to fuel the company’s growth. For example, at the end of 2006, Olympus Medical Systems set its sight on accelerating the process of bringing the Olympus 5.5 mm hysteroscopy system to market for Conceptus, Inc.’s Essure, a permanent birth control system, by establishing a strategic alliance. The Essure is the first hysteroscopy-based sterilization method that has received FDA approval in the United States.
In addition, early 2007 brought the launch of Olympus’s new Endo-Flush Endoscope Flushing Pump EFP250. Released in February, the pump replaces manual flushing by using a syringe with an automatic pump in the cleaning process.
In more recent product news, in June, Olympus Medical Systems added the Single Balloon Enteroscope System to its list of product offerings to support endoscopic diagnosis and the treatment of conditions in the small bowel area. A month earlier, Olympus and VisEn Medical Inc. also announced three new types of VisEn In Vivo Near Infrared Fluorescence Probes. The probes were made available in Japan and four other Asian markets. Parent company Olympus Corp. has pursued overall expansion by opening two new eco-friendly facilities. The Mishima Facility in Sunto-gun, Shizuoka Prefecture, which opened in April 2007 in Japan, now houses development, quality assurance and customer support operations for Olympus Corp.’s diagnostic business, among other uses. (The diagnostic business, which falls into the company’s Life Sciences division and encompasses Olympus’s blood analyzers, had a slower climb in FY 2006, with sales only growing by 8.7% to just under $400 million.)
In addition, KeyMed Ltd., a consolidated subsidiary of the Olympus Corp. that manufactures medical and industrial equipment, established a new plant for its medical devices at Southend-on-Sea in the United Kingdom in May 2007.
Key Executives:
Tsuyoshi Kikukawa, Representative Director and President
Masaaki Terada, Director, Sr. Exec. Managing Officer
Tsuyoshi Kikukawa, President, Olympus Corp.
Haruhito Morishima, President, Olympus Medical Systems Corp.
Rick Harbuck, Group VP, Olympus America, Medical Systems Group
Michael C. Woodford, Exec. Managing Director, Olympus Medical Systems Europa GmbH
No. of Employees: 33,022
World Headquarters: Tokyo, Japan
For the year ended March 31, 2006, overall net sales for Olympus Corp. exceeded $8.6 billion, up 20.2% from the prior year. FY 2007, which closed at the end of March, didn’t quite measure up to the gains seen in 2006 but did close with an 8.6% gain.
Solid financial growth and a wide array of new product offerings contributed to a steady year for Olympus Medical Systems, which continues to explore new methods on expanding its reach domestically and overseas.
Olympus Medical Systems obtained solid marks with 15.5% growth of $2.35 billion reported in net sales in FY 2006. The bulk of sales came from overseas, with $1.7 billion attributed to international sales and more than $600 million in sales reported domestically. The largest growth between FY 2005 and FY 2006 occurred in Asia (48.9%), with double-digit increases also seen in North America (16.9%), Japan (11.3%), Europe (10%) and other regions (27%).
The company closed its FY 2007, ended March 31, with sustained growth in net sales totaling $2.7 billion, a 17% increase from FY 2006. Once again, the company achieved a double-digit increase (22.2%) overseas, but sales were flat (2.5% growth) domestically.
The company’s stronghold in the endoscope product line reaped 18.5% growth in FY 2006, reaching $1.5 billion in sales. In FY 2007, sales grew another 22% over the prior year, reaching $1.8 billion. Sales of minimally invasive products, which include surgical endoscopes and endo-therapy devices, grew 10.1% to $806 million in FY 2006 and climbed another 7.2% in FY 2007 to $836 million.
New products continue to fuel the company’s growth. For example, at the end of 2006, Olympus Medical Systems set its sight on accelerating the process of bringing the Olympus 5.5 mm hysteroscopy system to market for Conceptus, Inc.’s Essure, a permanent birth control system, by establishing a strategic alliance. The Essure is the first hysteroscopy-based sterilization method that has received FDA approval in the United States.
In addition, early 2007 brought the launch of Olympus’s new Endo-Flush Endoscope Flushing Pump EFP250. Released in February, the pump replaces manual flushing by using a syringe with an automatic pump in the cleaning process.
In more recent product news, in June, Olympus Medical Systems added the Single Balloon Enteroscope System to its list of product offerings to support endoscopic diagnosis and the treatment of conditions in the small bowel area. A month earlier, Olympus and VisEn Medical Inc. also announced three new types of VisEn In Vivo Near Infrared Fluorescence Probes. The probes were made available in Japan and four other Asian markets. Parent company Olympus Corp. has pursued overall expansion by opening two new eco-friendly facilities. The Mishima Facility in Sunto-gun, Shizuoka Prefecture, which opened in April 2007 in Japan, now houses development, quality assurance and customer support operations for Olympus Corp.’s diagnostic business, among other uses. (The diagnostic business, which falls into the company’s Life Sciences division and encompasses Olympus’s blood analyzers, had a slower climb in FY 2006, with sales only growing by 8.7% to just under $400 million.)
In addition, KeyMed Ltd., a consolidated subsidiary of the Olympus Corp. that manufactures medical and industrial equipment, established a new plant for its medical devices at Southend-on-Sea in the United Kingdom in May 2007.